BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32522271)

  • 21. Molecular pathways of human adrenocortical carcinoma - translating cell signalling knowledge into diagnostic and treatment options.
    Szyszka P; Grossman AB; Diaz-Cano S; Sworczak K; Dworakowska D
    Endokrynol Pol; 2016; 67(4):427-50. PubMed ID: 27387247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AXIN genetic analysis in adrenocortical carcinomas updated.
    Guimier A; Ragazzon B; Assié G; Tissier F; Dousset B; Bertherat J; Gaujoux S
    J Endocrinol Invest; 2013 Dec; 36(11):1000-3. PubMed ID: 23812285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.
    De Martino MC; Feelders RA; de Herder WW; van Koetsveld PM; Dogan F; Janssen JA; Waaijers AM; Pivonello C; Lamberts SW; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocr Relat Cancer; 2014 Aug; 21(4):601-13. PubMed ID: 24891456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
    Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
    J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
    Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
    Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epicardial function of canonical Wnt-, Hedgehog-, Fgfr1/2-, and Pdgfra-signalling.
    Rudat C; Norden J; Taketo MM; Kispert A
    Cardiovasc Res; 2013 Dec; 100(3):411-21. PubMed ID: 24000064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
    Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
    Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sonic hedgehog signaling is active in human adrenal cortex development and deregulated in adrenocortical tumors.
    Gomes DC; Leal LF; Mermejo LM; Scrideli CA; Martinelli CE; Fragoso MC; Latronico AC; Tone LG; Tucci S; Yunes JA; Cardinalli IA; Mastellaro MJ; Brandalise SR; Ramalho F; Moreira AC; Ramalho LN; de Castro M; Antonini SR
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1209-16. PubMed ID: 24712566
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Activating Variant in CTNNB1 is Associated with a Sclerosing Bone Dysplasia and Adrenocortical Neoplasia.
    Peng H; Jenkins ZA; White R; Connors S; Hunter MF; Ronan A; Zankl A; Markie DM; Daniel PB; Robertson SP
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31970420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
    Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular markers and targeted therapies for adrenocortical carcinoma.
    Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
    Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
    He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
    Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
    Ragazzon B; Libé R; Gaujoux S; Assié G; Fratticci A; Launay P; Clauser E; Bertagna X; Tissier F; de Reyniès A; Bertherat J
    Cancer Res; 2010 Nov; 70(21):8276-81. PubMed ID: 20959480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A reappraisal of transcriptional regulation by NR5A1 and beta-catenin in adrenocortical carcinoma.
    Lalli E
    Front Endocrinol (Lausanne); 2023; 14():1303332. PubMed ID: 38155952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of Forkhead Box Protein O1 (FOXO1) Transcription Factor May Promote Adrenocortical Tumorigenesis.
    Stenman A; Murtha T; Korah R; Carling T
    Horm Metab Res; 2017 Aug; 49(8):631-637. PubMed ID: 28641336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways.
    Yang ZQ; Moffa AB; Haddad R; Streicher KL; Ethier SP
    Int J Cancer; 2007 Sep; 121(6):1265-73. PubMed ID: 17520678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
    Pereira SS; Máximo V; Coelho R; Batista R; Soares P; Guerreiro SG; Sobrinho-Simões M; Monteiro MP; Pignatelli D
    J Cell Biochem; 2017 Aug; 118(8):2064-2071. PubMed ID: 27886397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
    Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
    Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.